Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2026 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform

LOS ANGELES, April 02, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology and AI-driven...
April 02, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
April 01, 2026 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell...
March 30, 2026 05:46 ET | Source: Research and Markets

Paraganglioma Market Trends and Investment Opportunities 2026-2030

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Paraganglioma Market Report 2026" has been added to ResearchAndMarkets.com's offering.The paraganglioma market is on an upward trajectory, with...
March 23, 2026 11:15 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology Announces FDA Clearance of Investigator-Initiated IND to Advance Phase 1 Study in Recurrent High-Grade Glioma

Siren Biotechnology Announces FDA Clearance of Investigator-Initiated IND to Advance Phase 1 Study in Recurrent High-Grade Glioma
March 19, 2026 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01

STAFFORD, Texas, March 19, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
March 18, 2026 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Provides Update on Upcoming AACR Meeting

STAFFORD, Texas, March 18, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
March 17, 2026 16:30 ET | Source: Immunocore Holdings plc

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 17 March...
March 16, 2026 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01

STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
March 13, 2026 12:30 ET | Source: Tevogen Bio Inc

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence platform,...